NO20091970L - Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion - Google Patents

Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion

Info

Publication number
NO20091970L
NO20091970L NO20091970A NO20091970A NO20091970L NO 20091970 L NO20091970 L NO 20091970L NO 20091970 A NO20091970 A NO 20091970A NO 20091970 A NO20091970 A NO 20091970A NO 20091970 L NO20091970 L NO 20091970L
Authority
NO
Norway
Prior art keywords
quinazolin
pyrrol
piperazin
indol
dione
Prior art date
Application number
NO20091970A
Other languages
English (en)
Norwegian (no)
Inventor
Piotr Karpinski
Paul Allen Sutton
Dimitris Papoutsakis
Stephanie Monnier
Elias Ndzie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091970(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20091970L publication Critical patent/NO20091970L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20091970A 2006-10-20 2009-05-20 Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion NO20091970L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85338406P 2006-10-20 2006-10-20
PCT/US2007/022241 WO2008051440A1 (en) 2006-10-20 2007-10-18 Crystal modifications -3- (1h-ind0l-3-yl) -4- [2- (4-methyl-piperazin-1-yl) -quinazolin-4-yl] -pyrrole-2, 5-d ione

Publications (1)

Publication Number Publication Date
NO20091970L true NO20091970L (no) 2009-05-20

Family

ID=38921707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091970A NO20091970L (no) 2006-10-20 2009-05-20 Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion

Country Status (23)

Country Link
US (1) US8865897B2 (pt)
EP (1) EP2102195A1 (pt)
JP (1) JP5302199B2 (pt)
KR (1) KR20090073231A (pt)
CN (2) CN103265533A (pt)
AR (1) AR063491A1 (pt)
AU (1) AU2007309558B2 (pt)
BR (1) BRPI0717461A2 (pt)
CA (1) CA2666965A1 (pt)
CL (1) CL2007003006A1 (pt)
EC (1) ECSP099344A (pt)
IL (1) IL197962A (pt)
MA (1) MA30886B1 (pt)
MX (1) MX2009004048A (pt)
MY (1) MY158026A (pt)
NO (1) NO20091970L (pt)
NZ (1) NZ576241A (pt)
PE (1) PE20081133A1 (pt)
RU (1) RU2481341C2 (pt)
TN (1) TN2009000147A1 (pt)
TW (1) TWI399374B (pt)
WO (1) WO2008051440A1 (pt)
ZA (1) ZA200902048B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0808354A2 (pt) * 2007-03-09 2014-07-29 Novartis Ag Sais de 3-(1h-indol-3-il)-4-[2-(4-metil-piperazin-1-il)-quinazolin-4 -il]-pirrola-2,5-diona
US9017528B2 (en) 2011-04-14 2015-04-28 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9005409B2 (en) 2011-04-14 2015-04-14 Tel Nexx, Inc. Electro chemical deposition and replenishment apparatus
US9303329B2 (en) 2013-11-11 2016-04-05 Tel Nexx, Inc. Electrochemical deposition apparatus with remote catholyte fluid management

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2070921A1 (en) * 2000-11-07 2009-06-17 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
AU2008266515B2 (en) 2007-06-18 2014-05-01 Sanofi Pyrrole derivatives as P2Y12 antagonists

Also Published As

Publication number Publication date
WO2008051440A1 (en) 2008-05-02
US20100041884A1 (en) 2010-02-18
MA30886B1 (fr) 2009-11-02
IL197962A0 (en) 2009-12-24
CN101522664A (zh) 2009-09-02
ECSP099344A (es) 2009-06-30
EP2102195A1 (en) 2009-09-23
TWI399374B (zh) 2013-06-21
CN103265533A (zh) 2013-08-28
CA2666965A1 (en) 2008-05-02
TW200829572A (en) 2008-07-16
MY158026A (en) 2016-08-30
BRPI0717461A2 (pt) 2013-10-08
RU2481341C2 (ru) 2013-05-10
NZ576241A (en) 2012-05-25
MX2009004048A (es) 2009-04-27
AU2007309558A1 (en) 2008-05-02
AU2007309558B2 (en) 2012-05-24
RU2009118816A (ru) 2010-11-27
KR20090073231A (ko) 2009-07-02
ZA200902048B (en) 2010-01-27
CL2007003006A1 (es) 2008-05-23
AR063491A1 (es) 2009-01-28
US8865897B2 (en) 2014-10-21
CN101522664B (zh) 2013-06-12
PE20081133A1 (es) 2008-09-16
JP2010506927A (ja) 2010-03-04
JP5302199B2 (ja) 2013-10-02
IL197962A (en) 2013-08-29
TN2009000147A1 (en) 2010-10-18

Similar Documents

Publication Publication Date Title
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
EA200800201A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA201000093A1 (ru) Производные пиридазинона
ATE479687T1 (de) Kinaseinhibitoren
TN2010000131A1 (en) Polo-like kinase inhibitors
DOP2013000072A (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.
UY30639A1 (es) Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
WO2008017361A3 (de) 2-(heterocyclylbenzyl)-pyridazinonderivate
EA200970019A1 (ru) Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил]пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
MX2012008083A (es) Inhibidores de triazol y oxazol quinaza.
NZ592897A (en) Crystals of laquinimod sodium, and process for the manufacture thereof
EA201100966A1 (ru) Производные пиридазинона
NO20091299L (no) Substituerte sulfonamidderivater
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
ATE542800T1 (de) Kinasehemmer und ihre anwendungsverfahren
NO20082096L (no) Azaindol-2-karboksamidderivativer
HK1222396A1 (zh) 作为选择性蛋白质激酶抑制剂之苯并咪唑衍生物
EA201100872A1 (ru) Производные хиназолинамида
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
EA201000618A1 (ru) 5-цианотиенопиридины для лечения опухолей
NO20091970L (no) Krystallmodifikasjoner av 3-(1,H-indol-3-yl)-4-[2-(4-metyl-piperazin-1-yl)-quinazolin-4-yl]-pyrrol-2,5-dion
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application